AAAAAA
Results: 1-25/36
Authors:
Brekke, MK
Lieberman, R
Wright, E
Green, DR
Citation: Mk. Brekke et al., Posterior facet talocalcaneal coalition, J AM POD M, 91(8), 2001, pp. 422-426
Authors:
Liu, YQ
Kyle, E
Patel, S
Housseau, F
Hakim, F
Lieberman, R
Pins, M
Blagosklonny, MV
Bergan, RC
Citation: Yq. Liu et al., Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells, PROSTATE C, 4(2), 2001, pp. 81-91
Authors:
Geske, FJ
Lieberman, R
Strange, R
Gerschenson, LE
Citation: Fj. Geske et al., Early stages of p53-induced apoptosis are reversible, CELL DEAT D, 8(2), 2001, pp. 182-191
Authors:
Menter, DG
Hoque, A
Motiwala, N
Sahin, AA
Sneige, N
Lieberman, R
Lippman, SM
Citation: Dg. Menter et al., Computerized image analysis of Ki-67 in ductal breast carcinoma in situ, ANAL QUAN C, 23(3), 2001, pp. 218-228
Authors:
Carroll, PR
Fair, WR
Grossfeld, GD
Heston, WDW
Lieberman, R
Malkowicz, SB
Stricker, HJ
Sylvester, J
Peehl, DM
Meyer, F
Hart, C
Citation: Pr. Carroll et al., Overview consensus statement, UROLOGY, 58(2A), 2001, pp. 1-4
Authors:
Fair, WR
Stricker, HJ
Lieberman, R
Bubley, GJ
Trachtenberg, J
Heston, WDW
Citation: Wr. Fair et al., Discussion following Dr. Hans J. Stricker's presentations, UROLOGY, 58(2A), 2001, pp. 27-27
Authors:
Lieberman, R
Gleave, ME
Carroll, PR
Bubley, GJ
Citation: R. Lieberman et al., Discussion following Dr. Martin E. Gleave's presentation, UROLOGY, 58(2A), 2001, pp. 48-49
Authors:
Lieberman, R
Citation: R. Lieberman, Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent development, UROLOGY, 58(2A), 2001, pp. 83-90
Authors:
Lieberman, R
Lubeck, DP
Trachtenberg, J
Stricker, HJ
Newling, DWW
Fair, WR
Carroll, PR
Citation: R. Lieberman et al., The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 99-100
Authors:
Newling, DWW
Daniell, HW
Lieberman, R
Sylvester, J
Trachtenberg, J
Citation: Dww. Newling et al., Osteoporosis due to androgen deprivation therapy in men with prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 106-107
Authors:
Lieberman, R
Nelson, WG
Citation: R. Lieberman et Wg. Nelson, New clinical trial strategies for prostate cancer prevention - Introduction, UROLOGY, 57(4A), 2001, pp. 1-3
Authors:
Lieberman, R
Nelson, WG
Sakr, WA
Meysken, FL
Klein, EA
Wilding, G
Partin, AW
Lee, JJ
Lippman, SM
Citation: R. Lieberman et al., Executive summary of the National Cancer Institute Workshop: Highlights and recommendations, UROLOGY, 57(4A), 2001, pp. 4-27
Authors:
Kelloff, GJ
Lieberman, R
Seele, VE
Boone, CM
Lubet, RA
Kopelovich, L
Malone, WA
Crowell, JA
Higley, HR
Sigman, CC
Citation: Gj. Kelloff et al., Acents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer, UROLOGY, 57(4A), 2001, pp. 46-51
Authors:
Boone, CW
Lieberman, R
Mairinger, T
Palcic, B
Bacus, J
Bartels, P
Citation: Cw. Boone et al., Computer-assisted image analysis-derived intermediate endpoints, UROLOGY, 57(4A), 2001, pp. 129-131
Authors:
Lopacznski, W
Hruszkewycz, AM
Lieberman, R
Citation: W. Lopacznski et al., Preprostatectomy: A clinical model to study stromal-epithelial interactions, UROLOGY, 57(4A), 2001, pp. 194-199
Authors:
Lee, JD
Lieberman, R
Sloan, JA
Piantadosi, S
Lippman, SM
Citation: Jd. Lee et al., Design considerations for efficient prostate cancer chemoprevention trials, UROLOGY, 57(4A), 2001, pp. 205-212
Authors:
Weiss, HL
Urban, DA
Grizzle, WE
Cronin, KA
Freedman, LS
Kelloff, GJ
Lieberman, R
Citation: Hl. Weiss et al., Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer, UROLOGY, 57(4A), 2001, pp. 220-223
Authors:
Lieberman, R
Citation: R. Lieberman, Prostate cancer chemoprevention: Strategies for designing efficient clinical trials, UROLOGY, 57(4A), 2001, pp. 224-229
Authors:
Lieberman, R
Citation: R. Lieberman, Chemoprevention of superficial bladder cancer, CANC TREAT, 2001, pp. 237-254
Authors:
Greenwald, P
Lieberman, R
Citation: P. Greenwald et R. Lieberman, Chemoprevention trials for prostate cancer, CONT CANC R, 2001, pp. 499-518
Authors:
Lieberman, R
Citation: R. Lieberman, HIV in older Americans: An epidemiologic perspective, J MIDWIFE W, 45(2), 2000, pp. 176-182
Authors:
Geske, FJ
Nelson, AC
Lieberman, R
Strange, R
Sun, T
Gerschenson, LE
Citation: Fj. Geske et al., DNA repair is activated in early stages of p53-induced apoptosis, CELL DEAT D, 7(4), 2000, pp. 393-401
Authors:
Singletary, E
Lieberman, R
Atkinson, N
Sneige, N
Sahin, A
Tolley, S
Colchin, M
Bevers, T
Stelling, C
Fornage, B
Fritsche, H
Hittelman, W
Kelloff, G
Lippman, SM
Citation: E. Singletary et al., Novel translational model for breast cancer chemoprevention study: Accrualto a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide, CANC EPID B, 9(10), 2000, pp. 1087-1090
Authors:
Liu, YQ
Kyle, E
Lieberman, R
Crowell, J
Kelloff, G
Bergan, RC
Citation: Yq. Liu et al., Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation, CLIN EXP M, 18(3), 2000, pp. 203-212
Authors:
Kelloff, GJ
Crowell, JA
Steele, VE
Lubet, RA
Malone, WA
Boone, CW
Kopelovich, L
Hawk, ET
Lieberman, R
Lawrence, JA
Ali, I
Viner, JL
Sigman, CC
Citation: Gj. Kelloff et al., Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents, J NUTR, 130(2), 2000, pp. 467S-471S